26 Aug 2021
ACROSTUDY data indicates that growth hormone blocker, pegvisomant, is safe and effective for long-term use in acromegaly patients. The full multi-centre report is published in the European Journal of Endocrinology.
New study suggests interacting with dogs can reduce cortisol levels
15 Mar 2024
Diabetes risk may be reduced by prioritising plant-based food
15 Mar 2024
Obesity in primary school aged girls linked to high incidence of musculoskeletal symptoms
15 Mar 2024
Risk of endometrial cancer associated with endocrine disrupting chemicals (EDCs)
15 Mar 2024